Cargando…

Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories

Influenza is a viral infection that affects much of the global population each year. Vaccination remains the most effective tool for preventing the disease. Live attenuated influenza vaccine (LAIV) has been used since the 1950s to protect humans against seasonal influenza. LAIVs developed by the Ins...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rudenko, Larisa, Yeolekar, Leena, Kiseleva, Irina, Isakova-Sivak, Irina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357706/ https://www.ncbi.nlm.nih.gov/pubmed/27593158 http://dx.doi.org/10.1016/j.vaccine.2016.08.018

Ejemplares similares

Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses
por: Shcherbik, Svetlana, et al.
Publicado: (2015)

Live Attenuated Reassortant Vaccines Based on A/Leningrad/134/17/57 Master Donor Virus Against H5 Avian Influenza
por: Kiseleva, Irina, et al.
Publicado: (2017)

Genotyping assay for differentiation of wild-type and vaccine viruses in subjects immunized with live attenuated influenza vaccine
por: Matyushenko, Victoria, et al.
Publicado: (2017)

Contribution of Neuraminidase of Influenza Viruses to the Sensitivity to Sera Inhibitors and Reassortment Efficiency
por: Kiseleva, Irina, et al.
Publicado: (2014)

Sequential Immunization with Universal Live Attenuated Influenza Vaccine Candidates Protects Ferrets against a High-Dose Heterologous Virus Challenge
por: Isakova-Sivak, Irina, et al.
Publicado: (2019)

M2e-based universal influenza vaccines: a historical overview and new approaches to development
por: Mezhenskaya, Daria, et al.
Publicado: (2019)

Safety, Immunogenicity, and Protective Efficacy of a Chimeric A/B Live Attenuated Influenza Vaccine in a Mouse Model
por: Stepanova, Ekaterina, et al.
Publicado: (2021)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell responses
por: Matyushenko, Victoria, et al.
Publicado: (2020)

Two Live Attenuated Vaccines against Recent Low–and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets
por: Rudenko, Larisa, et al.
Publicado: (2018)

Truncation of NS1 Protein Enhances T Cell-Mediated Cross-Protection of a Live Attenuated Influenza Vaccine Virus Expressing Wild-Type Nucleoprotein
por: Prokopenko, Polina, et al.
Publicado: (2023)

Universal Live-Attenuated Influenza Vaccine Candidates Expressing Multiple M2e Epitopes Protect Ferrets against a High-Dose Heterologous Virus Challenge
por: Mezhenskaya, Daria, et al.
Publicado: (2021)

Recombinant Live Attenuated Influenza Vaccine Viruses Carrying Conserved T Cell Epitopes of Human Adenoviruses Induce Functional Cytotoxic T Cell Responses and Protect Mice against both Infections
por: Isakova-Sivak, Irina, et al.
Publicado: (2020)

Prospects of and Barriers to the Development of Epitope-Based Vaccines against Human Metapneumovirus
por: Stepanova, Ekaterina, et al.
Publicado: (2020)

Generation and Characterization of Universal Live-Attenuated Influenza Vaccine Candidates Containing Multiple M2e Epitopes
por: Kotomina, Tatiana, et al.
Publicado: (2020)

A Live Probiotic Vaccine Prototype Based on Conserved Influenza a Virus Antigens Protect Mice against Lethal Influenza Virus Infection
por: Mezhenskaya, Daria, et al.
Publicado: (2021)

Immunogenicity and Cross Protection in Mice Afforded by Pandemic H1N1 Live Attenuated Influenza Vaccine Containing Wild-Type Nucleoprotein
por: Rekstin, Andrey, et al.
Publicado: (2017)

Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector
por: Isakova-Sivak, Irina, et al.
Publicado: (2022)

Live Attenuated Influenza H7N3 Vaccine is Safe, Immunogenic and Confers Protection in Animal Models
por: Rekstin, Andrey, et al.
Publicado: (2014)

Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine
por: Rudenko, Larisa, et al.
Publicado: (2015)

A Strategy to Elicit M2e-Specific Antibodies Using a Recombinant H7N9 Live Attenuated Influenza Vaccine Expressing Multiple M2e Tandem Repeats
por: Mezhenskaya, Daria, et al.
Publicado: (2021)

In Vitro Stimulation with Live SARS-CoV-2 Suggests Th17 Dominance In Virus-Specific CD4+ T Cell Response after COVID-19
por: Kudryavtsev, Igor, et al.
Publicado: (2022)

Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests
por: Rak, Alexandra, et al.
Publicado: (2022)

A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults
por: Kiseleva, Irina, et al.
Publicado: (2020)

RDE Treatment Prevents Non-Specific Detection of SARS-CoV-2- and Influenza-Specific IgG Antibodies in Heat-Inactivated Serum Samples
por: Goshina, Arina, et al.
Publicado: (2023)

Assessment of Human Immune Responses to H7 Avian Influenza Virus of Pandemic Potential: Results from a Placebo–Controlled, Randomized Double–Blind Phase I Study of Live Attenuated H7N3 Influenza Vaccine
por: Rudenko, Larisa, et al.
Publicado: (2014)

Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh
por: Lewis, Kristen D C, et al.
Publicado: (2019)

Phenotypic characteristics of novel swine‐origin influenza A/California/07/2009 (H1N1) virus
por: Kiseleva, Irina, et al.
Publicado: (2009)

Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview
por: Kudryavtsev, Igor, et al.
Publicado: (2022)

Assessment of Immunogenic and Antigenic Properties of Recombinant Nucleocapsid Proteins of Five SARS-CoV-2 Variants in a Mouse Model
por: Rak, Alexandra, et al.
Publicado: (2023)

Development of a Novel Live Attenuated Influenza A Virus Vaccine Encoding the IgA-Inducing Protein
por: Cáceres, C. Joaquín, et al.
Publicado: (2021)

Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine
por: Hilimire, Thomas A., et al.
Publicado: (2020)

Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin
por: Park, Bo Ryoung, et al.
Publicado: (2021)

Detection of IFNγ-Secreting CD4(+) and CD8(+) Memory T Cells in COVID-19 Convalescents after Stimulation of Peripheral Blood Mononuclear Cells with Live SARS-CoV-2
por: Matyushenko, Victoria, et al.
Publicado: (2021)

Understanding the Variability of Certain Biological Properties of H1N1pdm09 Influenza Viruses
por: Al Farroukh, Mohammad, et al.
Publicado: (2022)

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model
por: Rudenko, Larisa, et al.
Publicado: (2018)

Construction and Immunogenicity of a Novel Multivalent Vaccine Prototype Based on Conserved Influenza Virus Antigens
por: Kirsteina, Anna, et al.
Publicado: (2020)

Development and Pre-Clinical Evaluation of Two LAIV Strains against Potentially Pandemic H2N2 Influenza Virus
por: Isakova-Sivak, Irina, et al.
Publicado: (2014)

Non-Mouse-Adapted H1N1pdm09 Virus as a Model for Influenza Research
por: Kiseleva, Irina, et al.
Publicado: (2020)

A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines
por: White, Chantelle L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ll7lde92incbmdfu0jhm9brfq